FOXA2通过维持顶端MRP2表达防止急性肝衰竭中的高胆红素血症
本研究探讨急性肝衰竭(ALF)中多药耐药蛋白2(MRP2)的转录调控。在14例肝硬化和22例ALF患者肝组织中检测MRP2、FXR和FOXA2表达,并在原代肝细胞、Fxr-/-小鼠和LPS处理小鼠中研究调控机制。发现无脓毒症的ALF患者通过FOXA2上调MRP2维持顶端表达而不发生高胆红素血症,而合并脓毒症者FOXA2低表达、MRP2丢失并出现严重高胆红素血症;在Fxr-/-和LPS处理小鼠中异位表达FOXA2可恢复顶端MRP2并使血清胆红素正常化。
要点
- 生理状态下MRP2转录由核受体FXR/RXR复合物介导,Fxr-/-小鼠缺乏顶端MRP2并快速出现高胆红素血症。
- 无感染的ALF患者肝内FXR不可测但肝细胞表达FOXA2,维持顶端MRP2且不发生高胆红素血症。
- 合并脓毒症的ALF患者FOXA2低表达、MRP2丢失并出现严重高胆红素血症。
核心结论
- FOXA2替代FXR在无脓毒症的急性肝衰竭中维持MRP2表达。
- 异位表达FOXA2以维持MRP2是预防脓毒症相关急性肝衰竭高胆红素血症的潜在策略。
研究设计与样本
- 免疫组化检测14例肝硬化患者和22例急性肝衰竭患者肝组织中MRP2、FXR和FOXA2表达及临床病理关联。
- 在原代肝细胞、Fxr-/-小鼠和脂多糖(LPS)处理小鼠中研究MRP2调控机制。
主要发现
- 生理状态下稳态MRP2转录由核受体FXR/类视黄醇X受体复合物介导。
- Fxr-/-小鼠缺乏顶端MRP2表达并快速进展为高胆红素血症。
- 急性肝衰竭患者肝内FXR表达不可测,但无感染患者维持顶端MRP2表达且不发生高胆红素血症,这些患者肝细胞表达FOXA2。
- FOXA2通过结合MRP2启动子上调其转录;生理状态下胰岛素抑制FOXA2核转位。
- 急性肝衰竭中高水平胰高血糖素和肿瘤坏死因子α诱导肝细胞FOXA2表达及核转位。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Multidrug resistance protein 2 (MRP2) is a bottleneck in bilirubin excretion. Its loss is sufficient to induce hyperbilirubinaemia, a prevailing characteristic of acute liver failure (ALF) that is closely associated with clinical outcome. This study scrutinises the transcriptional regulation of MRP2 under different pathophysiological conditions. DESIGN: Hepatic MRP2, farnesoid X receptor (FXR) and Forkhead box A2 (FOXA2) expression and clinicopathologic associations were examined by immunohistochemistry in 14 patients with cirrhosis and 22 patients with ALF. MRP2 regulatory mechanisms were investigated in primary hepatocytes, Fxr -/- mice and lipopolysaccharide (LPS)-treated mice. RESULTS: Physiologically, homeostatic MRP2 transcription is mediated by the nuclear receptor FXR/retinoid X receptor complex. Fxr-/- mice lack apical MRP2 expression and rapidly progress into hyperbilirubinaemia. In patients with ALF, hepatic FXR expression is undetectable, however, patients without infection maintain apical MRP2 expression and do not suffer from hyperbilirubinaemia. These patients express FOXA2 in hepatocytes. FOXA2 upregulates MRP2 transcription through binding to its promoter. Physiologically, nuclear FOXA2 translocation is inhibited by insulin. In ALF, high levels of glucagon and tumour necrosis factor α induce FOXA2 expression and nuclear translocation in hepatocytes. Impressively, ALF patients with sepsis express low levels of FOXA2, lose MRP2 expression and develop severe hyperbilirubinaemia. In this case, LPS inhibits FXR expression, induces FOXA2 nuclear exclusion and thus abrogates the compensatory MRP2 upregulation. In both Fxr -/- and LPS-treated mice, ectopic FOXA2 expression restored apical MRP2 expression and normalised serum bilirubin levels. CONCLUSION: FOXA2 replaces FXR to maintain MRP2 expression in ALF without sepsis. Ectopic FOXA2 expression to maintain MRP2 represents a potential strategy to prevent hyperbilirubinaemia in septic ALF.
引用
- Wang S, Feng R, Wang SS, et al. FOXA2 prevents hyperbilirubinaemia in acute liver failure by maintaining apical MRP2 expression. Gut. 2022. PMID: 35444014. doi:10.1136/gutjnl-2022-326987
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。